Document is current
Any future updates will be listed below
-
Authors
Kawamura, Takahisa
Naito, Tateaki http://orcid.org/0000-0003-4047-2929
Kobayashi, Haruki
Nakashima, Kazuhisa
Omori, Shota
Wakuda, Kazushige
Ono, Akira
Kenmotsu, Hirotsugu
Murakami, Haruyasu
Endo, Masahiro
Takahashi, Toshiaki
- License Information
-
More Information
Article History
Received: 19 December 2018
Accepted: 25 July 2019
First Online: 2 August 2019
Ethics approval and consent to participate
: Not applicable as this is not an interventional study. The need for approval was waived by the Shizuoka Cancer Center Institutional Review Board.
: Written consent for publication was obtained from the patient described and is available for review.
: H.K. has received honoraria from Eli Lilly Japan K.K. and Taiho Pharmaceutical Co. Ltd. K.N. has received honoraria from Chugai Pharmaceutical Co. Ltd., Novartis Pharma K.K., and Taiho Pharmaceutical Co. Ltd. S.O. has received honoraria from Chugai Pharmaceutical Co. Ltd., Ono Pharmaceutical Co. Ltd., AstraZeneca K.K., Boehringer Ingelheim Japan Inc., Taiho Pharmaceutical Co. Ltd., and MSD K.K. K.W. has received honoraria from Eli Lilly Japan K.K., Chugai Pharmaceutical Co. Ltd., Taiho Pharmaceutical Co. Ltd., Boehringer Ingelheim Japan Inc., Ono Pharmaceutical Co. Ltd., and MSD K.K. A.O. has received honoraria from Chugai Pharmaceutical Co. Ltd., Novartis Pharma K.K., Ono Pharmaceutical Co. Ltd., Bristol-Myers Squibb Co. Ltd., and Taiho Pharmaceutical Co. Ltd.; and research funding from Chugai Pharmaceutical Co. Ltd. and Taiho Pharmaceutical Co. Ltd. H.K. has received honoraria from Eli Lilly Japan K.K., Chugai Pharmaceutical Co. Ltd., AstraZeneca K.K., Ono Pharmaceutical Co. Ltd., Boehringer Ingelheim Japan Inc., Novartis Pharma K.K., Bristol-Myers Squibb Co. Ltd., Kyowa Hakko Kirin Co. Ltd., and MSD K.K.; and research funding from AstraZeneca K.K., Chugai Pharmaceutical Co. Ltd. and Boehringer Ingelheim Japan Inc. H.M. has received honoraria from AstraZeneca K.K., Eli Lilly Japan K.K., Chugai Pharmaceutical Co. Ltd., Boehringer Ingelheim Japan Inc., Pfizer Inc., Taiho Pharmaceutical Co. Ltd., Novartis Pharma K.K., Bristol-Myers Squibb Co. Ltd., and Ono Pharmaceutical Co. Ltd. T.T. has received grants and honoraria from Ono Pharmaceutical Co. Ltd., MSD K.K., AstraZeneca K.K., Eli Lilly Japan K.K., Chugai Pharmaceutical Co. Ltd.; grants from Pfizer Inc.; and honoraria from Boehringer Ingelheim Japan Inc., and Roche Diagnostics K.K. The remaining author declares no conflict of interest.
